ACADIA Pharmaceuticals Inc. (ACAD)
NASDAQ: ACAD · Real-Time Price · USD
21.04
+0.15 (0.72%)
Jun 3, 2026, 12:17 PM EDT - Market open

ACADIA Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 21 analysts polled by S&P Global, ACADIA Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $31.65. The average 1-year stock price forecast is 50.43% higher than the current stock price, while the lowest is $17 (-19.20%) and the highest is $45 (+113.88%).

Price Target: $31.65 (+50.43%)
Analyst Consensus: Buy
TargetLowAverageMedianHigh
Price$17$31.65$32$45
Change-19.20%+50.43%+52.09%+113.88%

Analyst Ratings

The average analyst rating for ACADIA Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

RatingDec '25Jan '26Feb '26Mar '26Apr '26May '26
Strong Buy9911121212
Buy444444
Hold665444
Sell000000
Strong Sell111111
Total202021212121

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Oppenheimer
Oppenheimer
Hold
Maintains
$23
HoldMaintains$23+9.32%May 22, 2026
BMO Capital
BMO Capital
Buy
Maintains
$34
BuyMaintains$34+61.60%May 11, 2026
Unknown Analyst
Guggenheim
No rating
Guggenheim
Hold
Maintains
n/a
HoldMaintainsn/an/aMay 8, 2026
Citi
Citi
Buy
Maintains
$33$32
BuyMaintains$33$32+52.09%May 8, 2026
Bank of America Securities
Bank of America Securities
Buy
Maintains
n/a
BuyMaintainsn/an/aMay 7, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
1.24B
from 1.07B
Increased by 15.83%
Revenue Next Year
1.39B
from 1.24B
Increased by 11.88%
EPS This Year
0.39
from 2.30
Decreased by -83.15%
EPS Next Year
0.72
from 0.39
Increased by 85.69%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
484.15M517.24M726.44M957.80M1.07B1.24B
Revenue Growth
9.60%6.83%40.45%31.85%11.87%15.83%
Gross Profit
225.59M145.49M333.18M572.71M653.71M1.14B
Gross Margin
46.60%28.13%45.86%59.79%61.01%91.88%
Operating Income
-170.44M-223.60M-73.38M84.28M104.81M49.95M
Net Income
-167.87M-215.98M-61.29M226.45M391.00M66.50M
EPS
-1.05-1.34-0.371.362.300.39
EPS Growth
----69.12%-83.15%
Forward PE
--27.4035.9040.3854.30
Free Cash Flow
-65.26M-34.96M68.44M270.08M-54.82M204.10M
No. Analysts
-----21

Revenue Forecast

Revenue202620272028
High1.3B
Avg1.2B
Low1.2B

Revenue Growth

Revenue Growth202620272028
High
17.9%
Avg
15.8%
Low
14.2%

EPS Forecast

EPS202620272028
High0.61
Avg0.39
Low0.23

EPS Growth

EPS Growth202620272028
High
-73.5%
Avg
-83.2%
Low
-90.0%
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Financial forecast data provided by S&P Global Market Intelligence. The data is sourced from Wall Street analysts. Data sources.